Cooperative Agreement U01CA305196
Award Date 8/6/25
Completion Date 7/31/30
Dollars Obligated $942K
Federal Agency
Federal Grant Program
Assistance Type
Cooperative Agreement
Place of Performance
California, USA
Similar Awards
- This Cooperative Agreement award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $953,922.00 in funding to the Scripps Research Institute in California to conduct research on the links between RNA modifications, codon use, translation, and metabolism in cancer cells. The overall goal is to identify correlations between modification states of the translation apparatus and changes in codon occupancy and translation rate across cancer cell lines, particularly...
- This Project Grant award from the National Cancer Institute (NCI), under the federal Cancer Biology Research program (CFDA 93.396), provides $487,542 to the Beckman Research Institute of the City of Hope to conduct research aimed at understanding the role of mitochondrial RNA methylation in acute myeloid leukemia (AML), particularly for high-risk AML subtypes. The key objectives are to determine the functional importance of the mitochondrial methyltransferase METTL17 in AML pathogenesis, dissect...
- This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $734,435.00 in funding to the Beckman Research Institute of the City of Hope to conduct research aimed at overcoming resistance to BH3 mimetic drugs in the treatment of acute myeloid leukemia (AML), particularly in older patients. The key objectives are to define the molecular mechanisms underlying BH3 mimetic resistance in AML and evaluate whether targeting the ADSS2 enzyme,...
- This Cooperative Agreement award of $922,755.00 from the National Cancer Institute under the Cancer Biology Research program (CFDA 93.396) supports research at the University of Massachusetts Medical School (UMASS Medical) aimed at understanding the role of tRNA modification and translational remodeling in cancer progression and metastasis. The project will use advanced RNA mass spectrometry, sequencing, and ribosome profiling techniques to comprehensively catalog tRNA modification dynamics...
- This $615,999 Project Grant was awarded by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) to the Beckman Research Institute of the City of Hope, a nonprofit organization. The grant funds research to develop a "Targeted Telomere-Disrupting Oligonucleotide for Acute Myeloid Leukemia Therapy" over a 3-year period from Sep 1, 2023 to Aug 31, 2026. As a nonprofit research organization, Beckman Research Institute leverages its medical...
- This $738,698 Project Grant awarded by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to the Beckman Research Institute of the City of Hope supports research on a novel anti-CD38 targeted alpha therapy (TAT) combined with total marrow irradiation (TMLI) for the treatment of relapsed/refractory acute myelogenous leukemia (AML) in patients over 60 years old. The goal is to develop an innovative, organ-sparing radiotherapy approach that can safely escalate the radiation...
- This $517,090 federal Project Grant awarded by the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) to the Beckman Research Institute of the City of Hope supports innovative research aimed at understanding the role and function of a novel gene, A978, which is overexpressed in Philadelphia chromosome-positive and Philadelphia-like B-cell acute lymphoblastic leukemia (B-ALL). The key objectives of this 5-year project are to: 1) determine the biological effects of A978 in...
- This Cooperative Agreement award of $556,865.00 was provided by the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) to the Trustees of Tufts College to conduct research on "Stiffness-Mediated Genetic Selection of Cells". The project aims to investigate how the mechanical properties of a cell's substrate can drive the evolution of cell phenotypes and genotypes over sustained culture periods. The research will quantify how cell behaviors like growth, motility, and...
- This Cooperative Agreement award, funded by the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research), supports research to develop a non-invasive blood test for multi-cancer detection and determination of tissue of origin preceding overt cancer diagnosis. The $692,491 award, effective May 1, 2025 through April 30, 2030, will allow the University of Chicago to explore cancer-specific early epigenetic marks in circulating cell-free DNA and develop a highly sensitive...
- This $850,611 Cooperative Agreement award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) will support research at the University of Texas Southwestern Medical Center to investigate the role of tRNA modifications in regulating mitochondrial activity and cancer metastasis in renal cell carcinoma. The project aims to examine how overexpression of dihydrouridine synthase enzymes, which introduce dihydrouridine modifications in tRNAs, impacts the translation of...